期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
HCV infection, B-cell non-Hodgkin's lymphoma and immunochemotherapy: Evidence and open questions 被引量:1
1
作者 maria Christina Cox maria antonietta aloe-spiriti +6 位作者 Elena Cavalieri Eleonora Alma Elia Gigante Paola Begini Caterina Rebecchini Gianfranco Delle Fave Massimo Marignani 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2012年第3期46-53,共8页
There is plenty of data confirming that hepatitis C virus (HCV) infection is a predisposing factor for a B-cell non-Hodgkin's lymphoma (B-NHL) outbreak, while relatively few reports have addressed the role of HCV ... There is plenty of data confirming that hepatitis C virus (HCV) infection is a predisposing factor for a B-cell non-Hodgkin's lymphoma (B-NHL) outbreak, while relatively few reports have addressed the role of HCV in affecting B-NHL patients' outcome. HCV infection may influence the short-term outcome of B-NHL because of the emergence of severe hepatic toxicity (HT) during immunochemotherapy. Furthermore, the long term outcome of HCV-related liver disease and patients' quality of life will possibly be affected by Rituximab maintenance, multiple-lines of toxicity during chemotherapy and hematopoietic stem cell transplantation. In this review, data dealing with aggressive and low-grade B-NHL were separately analyzed. The few retrospective papers reporting on aggressive B-NHL patients showed that HCV infection is a risk factor for the outbreak of severe HT during treatment. This adverse event not infrequently leads to the reduction of treatment density and intensity. Existing papers report that low-grade B-NHL patients with HCV infection may have a more widespread disease, more frequent relapses or a lower ORR compared to HCV-negative patients. Notwithstanding, there is no statistical evidence that the prognosis of HCV-positive patients is inferior to that of HCV-negative subjects. HCV-positive prospective studies and longer follow-up are necessary to ascertain if HCV-positive B-NHL patients have inferior outcomes and if there are long term sequels of immunochemotherapies on the progression of liver disease. 展开更多
关键词 Marginal zone LYMPHOMA Diffuse large B cell LYMPHOMA Hepatitis C virus Non-Hodgkin’s LYMPHOMAS HEPATOTOXICITY Chemotherapy IMMUNOCHEMOTHERAPY Prognosis RITUXIMAB
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部